| Bioactivity | GSK-3β inhibitor 6 is a potent GSK-3β inhibitor with an IC50 value of 24.4 μM. GSK-3β inhibitor 6 shows high hepatocyte glucose uptake (38%). GSK-3β inhibitor 6 can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder[1]. |
| Invitro | GSK-3β inhibitor 6 (Compound B30, 0-30 μΜ, 30 min) shows good GSK-3β kinase inhibitory activity (IC50: 24.4 μM)[1].GSK-3β inhibitor 6 (5 μM, 3 h) shows high hepatocyte glucose uptake (38%) with no significant toxicity against HepG2 cells[1]. |
| In Vivo | GSK-3β inhibitor 6 (Compound 5k, oral administration, 20 mg/kg) shows favorable drug-like properties (t1/2: 1.41 h, Cmax: 288 ng/mL)[2]. Animal Model: |
| Name | GSK-3β inhibitor 6 |
| Formula | C20H17BrN4 |
| Molar Mass | 393.28 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Shuwen Han, et al. Structural-Based Optimizations of the Marine-Originated Meridianin C as Glucose Uptake Agents by Inhibiting GSK-3β. Mar Drugs. 2021 Mar 12;19(3):149. [2]. Shuwen Han, et al. Structure-Based design of Marine-derived Meridianin C derivatives as glycogen synthase kinase 3β inhibitors with improved oral bioavailability: From aminopyrimidyl-indoles to the sulfonyl analogues. Bioorg Chem. 2022 Feb;119:105537. |